<DOC>
	<DOCNO>NCT00252499</DOCNO>
	<brief_summary>The purpose study determine whether nonalcoholic fatty liver disease ( NAFLD ) associate altered peripheral hepatic insulin sensitivity investigate potential mechanism underlie insulin resistance NAFLD determine association hepatic peripheral insulin sensitivity , hepatic steatosis , dyslipidemia , inflammatory cytokine , glucose metabolism , beta-cell function body fat distribution .</brief_summary>
	<brief_title>Insulin Resistance Non-alcoholic Fatty Liver Disease</brief_title>
	<detailed_description>NAFLD nonalcoholic steatohepatitis ( NASH ) common liver disorder strongly associate obesity , type 2 diabetes dyslipidemia . The underlie pathophysiology fatty infiltration liver think related insulin resistance , almost universal find patient NAFLD . It also possible fat infiltration inflammation liver may impair insulin sensitivity , either locally liver , peripherally via action inflammatory cytokine . We hypothesize insulin resistance major causal factor lead fat deposition liver NAFLD , thus intervention aim improve insulin sensitivity result reduction hepatic inflammation steatosis . Specific Aim 1 : To determine cross-sectional study whether NAFLD associate altered peripheral hepatic insulin sensitivity study relationship hepatic steatosis , dyslipidemia , inflammatory cytokine , glucose metabolism , -cell function body fat distribution . Specific Aim 2 : To determine 6 month placebo-controlled double-blinded treatment study treatment rosiglitazone , insulin sensitizer , fenofibrate , triglyceride lower agent , improve hepatic well peripheral insulin sensitivity thereby improve hepatic steatosis inflammation subject NAFLD . The result propose study important implication understand mechanism underlie insulin resistance abnormality lipid glucose metabolism subject NAFLD design future study aim prevention treatment condition .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Age 1880 year old Controls : otherwise healthy Case subject : NAFLD liver biopsy within past 3 year presume NAFLD otherwise unexplained elevated ALT fatty liver CT ultrasound Able comply take 3 pill day 6 month followup safety visit Controls : history evidence hepatic steatosis Cases : Cirrhosis liver biopsy clinical exam fibrosis score Causes liver dysfunction NASH Use medication associate hepatic steatosis : glucocorticoid estrogens tamoxifen amiodarone accutane sertraline Use medication cause insulin resistance : niacin glucocorticoid antiHIV drug atypical antipsychotic Use lipidlowering medication except stable dose statin Use antiNASH drug : ursodeoxycholic acid betaine milk thistle Use coumadin Use nitrate Significant alcohol consumption : Average &gt; 20 grams/day In subject diabetes HbA1c &gt; 7.5 % use insulin metformin rosiglitazone pioglitazone Liver transaminases : Cases : ALT &gt; 5x upper limit normal Controls : ALT AST normal range Iron saturation &gt; 50 % Creatinine &gt; 1.5 mg/dl men &gt; 1.4 mg/dl woman Hematocrit &lt; 33 % Pregnancy lactation Significant weight loss within past 6 month control , since liver biopsy case subject , history significant coronary artery disease congestive heart failure Retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>beta cell function</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>non-alcoholic steatohepatitis</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>insulin sensitivity</keyword>
</DOC>